0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Catastrophic Visual Loss in a Patient With Friedreich Ataxia FREE

Neroli Porter, MBBS, FRANZCO; Susan M. Downes, MD, FRCOphth; Carl Fratter, MPhil, DipRCPath; Philip Anslow, MA, MBBChir, FRCR; Andrea H. Németh, MBBS, MRCP, DPhil (Oxon)
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2007;125(2):273-274. doi:10.1001/archopht.125.2.273.
Text Size: A A A
Published online

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder usually characterized by progressive early-onset ataxia. The most common ophthalmic manifestation of FRDA is optic neuropathy, which is usually late in onset, is slowly progressive, and rarely causes severe visual loss.1 The genetic basis of FRDA in most patients is the homozygous expansion of a GAA trinucleotide repeat within the first intron of the FRDA gene, which encodes the mitochondrial protein frataxin. Mutations in frataxin cause progressive iron accumulation in mitochondria. Four percent of patients are compound heterozygotes for the GAA expansion on one allele and a point mutation on the other.2 We describe a patient with FRDA who was a compound heterozygote for the GAA expansion and a Gly130Val missense mutation, developed rapid-onset catastrophic visual loss, and was found to have clinical, electrophysiological, and radiological evidence of a severe optic neuropathy. In addition, she had pattern dystrophy.To our knowledge, this is the first description of a patient with FRDA with this phenotype.

REPORT OF A CASE

A 59-year-old woman with known FRDA and diabetes was referred for investigation of progressive loss of vision in the left eye. Two months previously, her visual acuities were 6/6 OU. On her first visit to the ophthalmology department,her visual acuities were 6/6 OD and 6/24 OS. Electrophysiology revealed normal rod, cone, and pattern electroretinographic results. The electro-oculographic results were normal, but the pattern reversal visual evoked potential showed increased latency in the right eye and no response in the left eye, consistent with optic nerve or optic tract disease. Clinical examination and autofluorescence imaging revealed multiple yellowish deposits at both posterior poles, consistent with pattern dystrophy (Figure). There were no signs of diabetic retinopathy. Twelve months later, her visual acuities were bilateral light perception only, with pale featureless optic discs. A computed tomographic scan of the brain and orbits excluded mass lesions or intraorbital abnormalities, and magnetic resonance imaging revealed severe atrophy of the optic nerves, optic chiasm, and optic tract.

Place holder to copy figure label and caption
Figure.

Color image montages of the right (A)and left (B) posterior poles showing a pale optic nerve and scattered, flecklike,yellowish deposits. Autofluorescence image montages of the right (C) and left (D) posterior poles showing an increased autofluorescence signal in the areas of the flecklike deposits.

Graphic Jump Location

Genetic analysis revealed compound heterozygosity, with a GAA expansion on one allele and a G-to-T base substitution in exon 4 (Gly130Val) on the other. The mitochondrial point mutations associated with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) or MIDD (maternally inherited diabetes and deafness), MERRF (myoclonic epilepsy with ragged-red fibers), NARP (neuropathy, ataxia, and retinitis pigmentosa), and Leber hereditary optic neuropathy were not identified.

COMMENT

This patient with FRDA had visual loss of a rapidity and severity not previously described in FRDA. She was also noted to have a pattern dystrophy but had normal electroretinographic results and pattern electroretinographic results, suggesting that it is the optic nerve or optic tract disease that is causing the visual loss rather than the pattern dystrophy. Macular abnormalities have been described in autosomal dominant spinocerebellar ataxia type 7 but not previously in FRDA; thus, this may be a coincidental finding in our patient.3 It is possible that the pattern dystrophy observed in this case could be associated with a mutation in peripherin/RDS gene,4 the ELOVL4 gene,5 or as-yet-unknown genes.

The cause of optic atrophy in FRDA is unknown, but it occurs more frequently in patients with larger GAA repeats and also more frequently in compound heterozygotes than homozygotes.2 Furthermore, optic neuropathy emerges late in the course of disease and may be more frequent in compound heterozygotes who tend to survive longer. Optic atrophy is a heterogeneous disorder often caused by inherited or acquired abnormalities of mitochondrial function. Further investigation of the molecular mechanisms causing FRDA in compound heterozygotes may provide important insights into the underlying pathogenesis that leads to optic atrophy.

ARTICLE INFORMATION

Correspondence: Dr Németh, Department of Clinical Genetics, Churchill Hospital, Churchill Drive, Oxford OX37LJ,England (andrea.nemeth@imm.ox.ac.uk).

Financial Disclosure: None reported.

REFERENCES

Oppenheimer  DR Brain lesions in Friedreich's ataxia. Can J Neurol Sci 1979;6173- 176
PubMed
Cossee  MDurr  ASchmitt  M  et al.  Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45200- 206
PubMed Link to Article
David  GDurr  AStevanin  G  et al.  Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet 1998;7165- 170
PubMed Link to Article
Francis  PJSchultz  DWGregory  AM  et al.  Genetic and phenotypic heterogeneity in pattern dystrophy. Br J Ophthalmol 2005;891115- 1119
PubMed Link to Article
Bernstein  PSTammur  JSingh  N  et al.  Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene. Invest Ophthalmol Vis Sci 2001;423331- 3336
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Color image montages of the right (A)and left (B) posterior poles showing a pale optic nerve and scattered, flecklike,yellowish deposits. Autofluorescence image montages of the right (C) and left (D) posterior poles showing an increased autofluorescence signal in the areas of the flecklike deposits.

Graphic Jump Location

Tables

References

Oppenheimer  DR Brain lesions in Friedreich's ataxia. Can J Neurol Sci 1979;6173- 176
PubMed
Cossee  MDurr  ASchmitt  M  et al.  Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45200- 206
PubMed Link to Article
David  GDurr  AStevanin  G  et al.  Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet 1998;7165- 170
PubMed Link to Article
Francis  PJSchultz  DWGregory  AM  et al.  Genetic and phenotypic heterogeneity in pattern dystrophy. Br J Ophthalmol 2005;891115- 1119
PubMed Link to Article
Bernstein  PSTammur  JSingh  N  et al.  Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene. Invest Ophthalmol Vis Sci 2001;423331- 3336
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

602 Views
10 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs